In a report released today, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences, with a price target of $140.00. The company’s shares closed yesterday at $116.74.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bansal covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Vertex Pharmaceuticals, and Merck & Company. According to TipRanks, Bansal has an average return of 9.2% and a 58.72% success rate on recommended stocks.
Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $128.95, which is a 10.46% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $135.00 price target.
The company has a one-year high of $121.83 and a one-year low of $84.17. Currently, Gilead Sciences has an average volume of 6.66M.
Read More on GILD:
Disclaimer & DisclosureReport an Issue
- Gilead price target raised to $135 from $129 at Cantor Fitzgerald
- Gilead price target raised to $135 from $125 at Citi
- Gilead Sciences: Strategic Positioning and Extended Patent Protection Justify Buy Rating
- Wells says Biktarvy patent settlement ‘big deal’ for Gilead at, $6-$12 upside
- Gilead Sciences Settles Patent Litigation on Biktarvy
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
/Elon%20Musk%2C%20founder%2C%20CEO%2C%20and%20chief%20engineer%20of%20SpaceX%2C%20CEO%20of%20Tesla%20by%20Frederic%20Legrand%20-%20COMEO%20via%20Shutterstock.jpg)
